GlobeNewswireMay 21, 2026IPO context
Liminatus Pharma said Nasdaq notified it that it failed to regain compliance with Nasdaq’s MVLS and MVPHS continued-listing requirements, leading to delisting from the Nasdaq Global Market unless the company requests an appeal by May 27, 2026, with trading of its common stock and warrants suspended at the open on May 29, 2026.